Abstract
Purpose :
To evaluate the safety and applicability of the TVRC-biopsy in the treatment and prognostication of patients with intraocular malignancy
Methods :
322 Patients referred to the Copenhagen Ocular Oncology unit with an intraocular tumor between 1th januar 2009 and 31th December 2016 was identified in the registry. 298 patients had a TVRC biopsy performed in relation to their primary treatment. 3 patients refused any treatment, 6 patients had external resection of the tumor and 15 patients declined to have a TVRC biopsy performed.
Results :
Histopathological diagnoses were obtained in 296 patients (99,3%). Genetic status for chromosome 3 was obtained in 258/280 cases with FISH (92,1%) and in 184/209 with MLPA (88,0%). For chromosome 8 the results were 254/280 with FISH (90,7%) and in 184/209 with MLPA (88%). In 282 out 290 patients (97,1%) either Fish or MLPA gave a genetic useful evaluation. 108 patients were primarily enucleated and 201 patients were treated with RU-106 brachytherapy. Cumulated incidence for retinal detachment surgery was 7.0 % after 8 years, but all retinas were attached without silicone oil in the eye at the end of the follow up.
32% of the patients that retained the eye had a visual acuity better than 0.5 after 6 years compared to 60% preoperatively. The major reason for vision loss was radiation and only 1 patient lost vision secondary to retinal detachment.
Conclusions :
TransVitreal-RetinoChoroidal biopsy technique is a valid method for obtaining material for both genetic and histological analyses. The cumulated incidence for retinal detachment surgery is 7% after 8 years. The retinal detachment seen after TVRC-biopsy Is characterized by subretinal string formation secondary to bleeding, rather than rhegmatogenous. Vision loss in the group was primarily related to radiation damage.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.